Executive Summary
HHS dominates with $1.19B across four contracts (28% of total), signaling sustained federal health IT, biopharma, and R&D spending through 2027+. NASA's $2.95B Caltech JPL modification anchors 68% of volume but offers neutral equity impact as a nonprofit.
Bullish signals in for-profit IT/services (Elevance, Emergent, ElbitAmerica, Pyramid) highlight $1.13B in reliable revenue ramps, with minimal outlays in newer awards indicating near-term cash flow acceleration.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 23, 2026.
Investment Signals (3)
- HHS Health IT & Biopharma Revenue Lock-in (HIGH)▲
Four HHS awards totaling $1.19B to Elevance, Emergent, RTI, and Mount Sinai provide multi-year visibility through 2027, with $694M already outlayed signaling steady execution.
- Defense/Security Contract Ramps (MEDIUM)▲
$105M DHS surveillance award to ElbitAmerica and $100M GSA IT BPA to Pyramid signal future revenue from 2026 starts, with options adding $4M+ potential.
- Nonprofit Dominance in R&D (HIGH)▲
Three nonprofits (Caltech, RTI, Mount Sinai) capture $3.21B (74% of total) in space/health R&D, limiting direct equity upside despite scale.
Risk Flags (3)
- Execution [HIGH RISK]▼
Long tenors (avg. end 2027+) across all contracts expose to funding cuts/delays, with $2.9B Caltech and $505M Elevance most extended.
- Market [MEDIUM RISK]▼
Firm fixed-price terms in Emergent ($422M) and Elbit ($105M) risk cost overruns; time-materials in Pyramid adds labor volatility.
- Regulatory [MEDIUM RISK]▼
Foreign-owned entities (Emergent Canada, ElbitAmerica) in HHS/DHS face scrutiny amid $527M obligations.
Opportunities (2)
- ◆
$201M+ in unexercised options (e.g., Caltech $202M, Emergent $284M, Mount Sinai $44M) across five contracts offer upside through 2029.
- ◆
Small business set-asides like Pyramid's $100M GSA BPA position for HUD/GSA IT expansion.
Sector Themes (3)
- ◆
60%+ non-NASA value ($1.19B) in HHS IT, biopharma, and analysis signals multi-year federal prioritization amid aging population needs.
- ◆
$2.95B NASA JPL mod underscores FFRDC reliance for Europa/missions through 2028.
- ◆
DHS/GSA awards ($205M) target surveillance/networks starting 2026 with extensions to 2030.
Watch List (4)
- 👁
{"entity"=>"Elevance Health (National Government Services)", "reason"=>"$505M CMS IT fully obligated through 2027 with $259M outlayed", "trigger"=>"Award fee realizations or subaward shifts >10%"}
- 👁
{"entity"=>"Emergent BioSolutions", "reason"=>"$422M VIGIV obligation +$284M options in biopharma thru 2029", "trigger"=>"Option exercises or outlay >$300M"}
- 👁
{"entity"=>"ElbitAmerica (Elbit Systems)", "reason"=>"$105M DHS surveillance from 2026 with foreign-ownership overlay", "trigger"=>"Initial outlays or policy reviews"}
- 👁
{"entity"=>"Pyramid Systems", "reason"=>"$100M small biz GSA BPA for HUD IT ending 2026", "trigger"=>"Extension to Sep 2026 or new call awards"}
Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 7 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals